Daljit Singh Aurora Sells 91,690 Shares of Neumora Therapeutics (NASDAQ:NMRA) Stock

Posted by Brian Himes on Aug 19th, 2026

Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) insider Daljit Singh Aurora sold 91,690 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1.50, for a total value of $137,535.00. Following the completion of the transaction, the insider directly owned 48,750 shares in the company, valued at $73,125. This trade represents a 65.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Daljit Singh Aurora also recently made the following trade(s):

On Wednesday, August 19th, Daljit Singh Aurora sold 30,918 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.65, for a total transaction of $51,014.70.
On Wednesday, August 19th, Daljit Singh Aurora sold 31,000 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.65, for a total value of $51,150.00.
On Monday, August 17th, Daljit Singh Aurora sold 55,016 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.50, for a total value of $82,524.00.
On Tuesday, August 18th, Daljit Singh Aurora sold 34,987 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.59, for a total value of $55,629.33.
On Tuesday, August 18th, Daljit Singh Aurora sold 34,162 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.58, for a total value of $53,975.96.

Neumora Therapeutics Stock Performance

Neumora Therapeutics stock remained flat at $1.64 during midday trading on Wednesday. The company had a trading volume of 716,090 shares, compared to its average volume of 699,708. Neumora Therapeutics, Inc. has a 12-month low of $0.83 and a 12-month high of $3.65. The stock has a fifty day simple moving average of $1.61 and a two-hundred day simple moving average of $2.11. The company has a debt-to-equity ratio of 1.19, a quick ratio of 5.09 and a current ratio of 4.50.

Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. As a group, sell-side analysts expect that Neumora Therapeutics, Inc. will post -0.85 EPS for the current fiscal year.

Institutional Trading of Neumora Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP bought a new position in Neumora Therapeutics during the 2nd quarter worth approximately $27,519,000. Bank of America Corp DE bought a new stake in shares of Neumora Therapeutics in the 2nd quarter valued at approximately $171,000. ADAR1 Capital Management LLC bought a new stake in shares of Neumora Therapeutics in the 2nd quarter valued at approximately $357,000. Canada Pension Plan Investment Board acquired a new stake in shares of Neumora Therapeutics during the 2nd quarter valued at approximately $337,000. Finally, The Manufacturers Life Insurance Company bought a new position in Neumora Therapeutics during the second quarter worth $44,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on NMRA. Royal Bank Of Canada reduced their price target on Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Weiss Ratings lowered Neumora Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 14th. Wall Street Zen upgraded Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday. Needham & Company LLC decreased their price target on shares of Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a research report on Tuesday, June 16th. Finally, Mizuho dropped their price target on shares of Neumora Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a research note on Thursday, June 18th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $6.57.

Read Our Latest Report on Neumora Therapeutics

Trending Headlines about Neumora Therapeutics

Here are the key news stories impacting Neumora Therapeutics this week:

Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $0.89 from $1.29 and its FY2027 forecast to a loss of $0.68 from $1.25, indicating analysts expect substantially narrower losses over the next two years.
Positive Sentiment: The firm also improved its quarterly outlook, forecasting a Q3 2026 loss of $0.20 per share versus $0.32 previously and a Q4 2026 loss of $0.16 versus $0.30 previously.
Positive Sentiment: Longer-term estimates were upgraded sharply: FY2028’s projected loss narrowed to $0.52 from $1.10, FY2029 moved to projected profit of $0.20 from a $0.26 loss, and FY2030 profit expectations increased to $1.83 from $1.51 per share. These changes imply a faster potential transition to profitability.
Positive Sentiment: HC Wainwright’s current estimates call for losses of $0.15, $0.16, $0.19 and $0.17 per share in the first four quarters of 2027, respectively, with full-year 2027 losses of $0.68. The firm’s continued Buy rating provides additional support for investor sentiment.
Neutral Sentiment: Neumora remains unprofitable, with the broader current-year consensus at a loss of $0.93 per share. The company’s shares are trading well below their 200-day moving average and remain near the lower portion of their 12-month range, underscoring continued execution and financing risks despite the improved forecasts.

About Neumora Therapeutics

(Get Free Report)

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.